These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 19734850)

  • 41. Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer.
    Bostner J; Alayev A; Berman AY; Fornander T; Nordenskjöld B; Holz MK; Stål O
    Breast Cancer Res Treat; 2018 Feb; 168(1):17-27. PubMed ID: 29128895
    [TBL] [Abstract][Full Text] [Related]  

  • 42. High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer.
    Siesing C; Sorbye H; Dragomir A; Pfeiffer P; Qvortrup C; Pontén F; Jirström K; Glimelius B; Eberhard J
    PLoS One; 2017; 12(8):e0182512. PubMed ID: 28800641
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
    Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
    J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
    Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer.
    Nordenskjöld A; Fohlin H; Fornander T; Löfdahl B; Skoog L; Stål O
    Breast Cancer Res Treat; 2016 Nov; 160(2):313-322. PubMed ID: 27722840
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance.
    Brennan DJ; Jirstrom K; Kronblad A; Millikan RC; Landberg G; Duffy MJ; Rydén L; Gallagher WM; O'Brien SL
    Clin Cancer Res; 2006 Nov; 12(21):6421-31. PubMed ID: 17085655
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pre-clinical and clinical studies on the role of RBM3 in muscle-invasive bladder cancer: longitudinal expression, transcriptome-level effects and modulation of chemosensitivity.
    Wahlin S; Boman K; Moran B; Nodin B; Gallagher WM; Karnevi E; Jirström K
    BMC Cancer; 2022 Feb; 22(1):131. PubMed ID: 35109796
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer.
    Ellis MJ; Lin L; Crowder R; Tao Y; Hoog J; Snider J; Davies S; DeSchryver K; Evans DB; Steinseifer J; Bandaru R; Liu W; Gardner H; Semiglazov V; Watson M; Hunt K; Olson J; Baselga J
    Breast Cancer Res Treat; 2010 Jan; 119(2):379-90. PubMed ID: 19844788
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Does analysis of biomarkers in tumor cells in lymph node metastases give additional prognostic information in primary breast cancer?
    Falck AK; Fernö M; Bendahl PO; Rydén L
    World J Surg; 2010 Jul; 34(7):1434-41. PubMed ID: 20213203
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Expression of both estrogen receptor-beta 1 (ER-β1) and its co-regulator steroid receptor RNA activator protein (SRAP) are predictive for benefit from tamoxifen therapy in patients with estrogen receptor-alpha (ER-α)-negative early breast cancer (EBC).
    Yan Y; Li X; Blanchard A; Bramwell VH; Pritchard KI; Tu D; Shepherd L; Myal Y; Penner C; Watson PH; Leygue E; Murphy LC
    Ann Oncol; 2013 Aug; 24(8):1986-93. PubMed ID: 23579816
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nuclear T-STAR protein expression correlates with HER2 status, hormone receptor negativity and prolonged recurrence free survival in primary breast cancer and decreased cancer cell growth in vitro.
    Sernbo S; Borrebaeck CA; Uhlén M; Jirström K; Ek S
    PLoS One; 2013; 8(7):e70596. PubMed ID: 23923007
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer.
    Jerevall PL; Jansson A; Fornander T; Skoog L; Nordenskjöld B; Stål O
    Breast Cancer Res; 2010; 12(4):R53. PubMed ID: 20649975
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial.
    Knoop AS; Lænkholm AV; Jensen MB; Nielsen KV; Andersen J; Nielsen D; Ejlertsen B;
    Eur J Cancer; 2014 May; 50(8):1412-21. PubMed ID: 24675287
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Overexpression of c-Myc and Bcl-2 during progression and distant metastasis of hormone-treated breast cancer.
    Planas-Silva MD; Bruggeman RD; Grenko RT; Smith JS
    Exp Mol Pathol; 2007 Feb; 82(1):85-90. PubMed ID: 17046747
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pak1, adjuvant tamoxifen therapy, and breast cancer recurrence risk in a Danish population-based study.
    Ahern TP; Cronin-Fenton DP; Lash TL; Sørensen HT; Ording AG; Hamilton-Dutoit SJ; Hellberg Y
    Acta Oncol; 2016 Jun; 55(6):734-41. PubMed ID: 27056567
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes.
    Habibi G; Leung S; Law JH; Gelmon K; Masoudi H; Turbin D; Pollak M; Nielsen TO; Huntsman D; Dunn SE
    Breast Cancer Res; 2008; 10(5):R86. PubMed ID: 18925950
    [TBL] [Abstract][Full Text] [Related]  

  • 57. bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study.
    Elledge RM; Green S; Howes L; Clark GM; Berardo M; Allred DC; Pugh R; Ciocca D; Ravdin P; O'Sullivan J; Rivkin S; Martino S; Osborne CK
    J Clin Oncol; 1997 May; 15(5):1916-22. PubMed ID: 9164202
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients.
    Liu S; Chia SK; Mehl E; Leung S; Rajput A; Cheang MC; Nielsen TO
    Breast Cancer Res Treat; 2010 Jan; 119(1):53-61. PubMed ID: 19205877
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study.
    Elledge RM; Green S; Pugh R; Allred DC; Clark GM; Hill J; Ravdin P; Martino S; Osborne CK
    Int J Cancer; 2000 Mar; 89(2):111-7. PubMed ID: 10754487
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer.
    Borgquist S; Jögi A; Pontén F; Rydén L; Brennan DJ; Jirström K
    Breast Cancer Res; 2008; 10(5):R79. PubMed ID: 18808688
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.